Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Castration Resistant Prostate Cancer: Developments & Challenges in 2020

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

Nivolumab: targeting PD-1 to bolster antitumor immunity

NICE recommends nivolumab plus ipilimumab for untreated advanced kidney cancer in intermediate or poor-risk patients - ecancer

VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) - The Lancet Oncology

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

JPM, Free Full-Text